Research programme: esterase-sensitive motif targeted therapeutics - Chroma Therapeutics

Drug Profile

Research programme: esterase-sensitive motif targeted therapeutics - Chroma Therapeutics

Latest Information Update: 10 Sep 2013

Price : $50

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action DNA inhibitors; Histone deacetylase inhibitors; HSP90 heat-shock protein inhibitors; Macrophage colony stimulating factor inhibitors; P38 mitogen-activated protein kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 10 Sep 2013 Preclinical development is ongoing in United Kingdom
  • 24 Aug 2010 Milestone payment made by GlaxoSmithKline to Chroma Therapeutics
  • 23 Jun 2009 Preclinical trials in Inflammation in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top